A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1689-1696

  Friday, Benjamin ^a   Lassere, Yvonne ^b   Meyers, Christina A ^b   Mita, Akira ^c   Abbruzzese, James L ^b   Thomas, Melanie B ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Taiho Pharmaceutical Co Ltd   (Singapore)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

3 C ethynylcytidine; Neurotoxicity; Nucleoside; Pharmacodynamics; Pharmacokinetics; Phase I; Solid malignancies; TAS 106

Indexed keywords

3' ETHYNYLCYTIDINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EXFOLIATIVE DERMATITIS; FEMALE; FINGER HYPERESTHESIA; FOOT HYPERESTHESIA; GALLBLADDER CARCINOMA; HAND HYPERESTHESIA; HEART INFARCTION; HUMAN; HYPERESTHESIA; HYPESTHESIA; INTESTINE OBSTRUCTION; IRON DEFICIENCY ANEMIA; LEIOMYOSARCOMA; LEUKOPENIA; LUNG CANCER; MALE; MYALGIA; NAUSEA; NEURITIS; ORTHOSTATIC HYPOTENSION; PAIN; PANCREAS CANCER; PARESTHESIA; PERIPHERAL NEURITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TOE HYPERESTHESIA; TREMOR; VASODILATATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84861497676     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hattori H, Tanaka M, Fukushima M, Sasaki T and Matsuda A: Nucleosides and nucleotides. 158. 1-(3-C-Ethynyl-beta-D-ribopentofuranosyl)- cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39(25): 5005-5011, 1996. (Pubitemid 26422516)
2. Burger K, Muhl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, Kellner M, Gruber-Eber A, Kremmer E, Holzel M and Eick D: Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 285(16): 12416-12425, 2010.
3. Tabata S, Tanaka M, Matsuda A, Fukushima M and Sasaki T: Antitumor effect of a novel multifunctional antitumor nucleoside, 3′-ethynylcytidine, on human cancers. Oncol Rep 3(6): 1029-1034, 1996.
4. Matsuda A, Fukushima M, Wataya Y and Sasaki T: A new antitumor nucleoside, 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd), is a potent inhibitor of RNA synthesis. Nucleosides Nucleotides 18(4-5): 811-814, 1999.
5. Azuma A, Matsuda A, Sasaki T and Fukushima M: 1-(3-CEthynyl-beta-D-ribo- pentofuranosyl) cytosine (ECyd, TAS- 106)1: antitumor effect and mechanism of action. Nucleosides Nucleotides Nucleic Acids 20(4-7): 609-619, 2001.
6. Murata D, Endo Y, Obata T, Sakamoto K, Syouji Y, Kadohira M, Matsuda A and Sasaki T: A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3′-ethynyl nucleosides. Drug Metab Dispose 32(10): 1178-1182, 2004. (Pubitemid 39287593)
7. Naito T, Yokogawa T, Kim HS, Matsuda A, Sasaki T, Fukushima M, Kitade Y and Wataya Y: An apoptotic pathway of 3′- ethynylcytidine (ECyd) involving the inhibition of RNA synthesis mediated by RNase L. Nucleic Acids Symp Ser 50: 103-104, 2006.
8. Kanda H, Takatori S, Matsuda A, Sasaki T, Tanaka M, Fukushima M and Wataya Y: Cytotoxic mechanisms of new antitumor nucleoside analogues, 3′-ethynylcytidine (ECyd) and 3′- ethynyluridine (EUrd). Nucleic Acids Symp Ser 37: 137-138, 1997.
9. Shimamoto Y, Fujioka A, Kazuno H, Murakami Y, Ohshimo H, Kato T, Matsuda A, Sasaki T and Fukushima M: Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta- D-ribo-pentofuranosyl)cytosine. Jpn J Cancer Res 92(3): 343- 351, 2001.
10. Ltd. TPC. TAS-106 Investigator Brochure. Tokyo, Japan, 2001.
11. Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A and Rowinskey EK: Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Invest New Drugs 30(1): 316-326, 2010.
12. Zubrod CG: Clinical investigations in cancer chemotherapy. J Chronic Dis 8(1): 183-190, 1958.
13. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1): 13-47, 2000 . (Pubitemid 30179675)
14. Matsuoka K, Kitamura R, Matsushima E and Kawaguchi Y: Determination of 3′-C-ethynylcytidine in human plasma and urine by liquid chromatographic-electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 31(1): 47-55, 2003.